To view this email as a web page, click here.
January 31, 2019
 
New developments in melanoma research
 
An update on immunotherapy for melanoma
IDO inhibitors have recently emerged as a new and exciting class of anticancer drugs. Learn more about this and other immunotherapy treatments in this article.
 
Possible tool to quickly assess BRAF, NRAS status
Cell-free circulating DNA (cfDNA) can provide a useful snapshot of the BRAF and NRAS genotype of melanoma patients' tumor tissue, a recent study suggests.
Advertisement
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.